Annual Review | The 2024 Hong Kong IPO rankings have been released! Mao Ge Ping and Lao Pu Gold surged over 70% on debut! Jingwei Tiandi made a spectacular profit of 6,560 HKD.

Hong Kong, as one of the important Global international financial centers, has been the largest Global IPO financing center seven times since 2009.

Futu NewsDec 20 18:30

Chuanxin Biotechnology-B (02509.HK): Non-executive Director Xue Mingyu has resigned.

On December 10, Glonhui reported that the non-executive director Xue Mingyu has submitted his resignation from his position as a non-executive director and member of the global strategy development committee due to personal matters requiring more time, effective from December 10, 2024. Xue Mingyu will serve as a consultant to the company.

Gelonghui FinanceDec 10 16:31

Kunxin Biotech-B(02509.HK): Supplemental application for QX001S (Ustekinumab Injection) for children with plaque psoriasis has been accepted.

On December 2nd, Glorious Exchange announced that Quanxin Biotechnology-B (02509.HK) has made public announcements regarding the framework agreement QX001S signed with Hangzhou ZMC East China Pharmaceutical Co., Ltd. ("ZMC East China"), with the publication date of September 12, 2024, containing information about the supplementary agreement of the "Ushikuzuma Monoclonal Antibody Contract Manufacturing Agreement" signed between ZMC East China and the company's subsidiary Jiangsu Safus Biotechnology Co., Ltd. ("Safus"), as well as the annual limit for the QX001S framework agreement. Additionally, an announcement was made on November 5, 2024, regarding ZMC East China receiving national pharmaceutical approvals.

Gelonghui FinanceDec 2 22:11

Hong Kong stock movement | Qianxin Biotech-B (02509) rises over 7% as the application for the marketing authorization of ustekinumab injection has been approved.

Hysan Bio-B (02509) increased by over 7%, as of the time of writing, it rose by 7.69%, trading at 14 Hong Kong dollars, with a transaction amount of 0.451 million Hong Kong dollars.

Zhitong FinanceNov 6 10:40

Sorrento Therapeutics-B (02509): QX001S (Selexin, Ustekinumab Injection) obtained the pharmaceutical registration certificate approved and issued by the National Medical Products Administration

Chun Shin Biologics -B (02509) issued an announcement. On November 5, 2024, Sino-American East received the National Pharmaceutical Administration...

Zhitong FinanceNov 5 17:33

Announcement Selection | CNOOC's net income in the first three quarters exceeded 116.6 billion yuan, a year-on-year increase of 19.5%; wuxi apptec orders in hand increased by more than 30% year-on-year.

①CNOOC's net income exceeded 110 billion yuan in the first 9 months, how fast is the growth? ②How is the profit performance of WuXi AppTec's year-on-year growth in hand orders?

cls.cnOct 29 07:52